Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy

被引:82
|
作者
Goldstein, Neal S.
Decker, David
Severson, Dawn
Schell, Scoff
Vicini, Frank
Margolis, Jeffrey
Dekhne, Nayana S.
机构
[1] William Beaumont Hosp, Dept Anat Pathol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Med Oncol, Royal Oak, MI 48072 USA
[3] William Beaumont Hosp, Dept Surg Oncol, Royal Oak, MI 48072 USA
[4] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48072 USA
关键词
molecular classification system; invasive breast cancer; complete pathologic response; neoadjuvant chemotherapy; receptor status;
D O I
10.1002/cncr.22981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. METHODS. Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. RESULTS. A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma,;01 of which were classified as luminal-A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR. CONCLUSIONS. The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.
引用
收藏
页码:1687 / 1696
页数:10
相关论文
共 50 条
  • [1] The safety of breast-conserving surgery in patients who achieve a complete Pathologic response after Neoadjuvant chemotherapy
    Peintinger, Florentia
    Symmans, W. Fraser
    Gonzalez-Angulo, Ana M.
    Boughey, Judy C.
    Buzdar, Aman U.
    Yu, T. Kuan
    Hunt, Kelly K.
    Singletary, S. Eva
    Babiera, Gildy V.
    Lucci, Anthony
    Meric-Bernstam, Funda
    Kuerer, Henry M.
    CANCER, 2006, 107 (06) : 1248 - 1254
  • [2] The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Peter Blumencranz
    Mehran Habibi
    Steve Shivers
    Geza Acs
    Lisa E. Blumencranz
    Erin B. Yoder
    Bastiaan van der Baan
    Andrea R. Menicucci
    Patricia Dauer
    William Audeh
    Charles E. Cox
    Annals of Surgical Oncology, 2023, 30 : 8353 - 8361
  • [3] The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Blumencranz, Peter
    Habibi, Mehran
    Shivers, Steve
    Acs, Geza
    Blumencranz, Lisa E.
    Yoder, Erin B.
    van der Baan, Bastiaan
    Menicucci, Andrea R.
    Dauer, Patricia
    Audeh, William
    Cox, Charles E.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (13) : 8353 - 8361
  • [4] ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Peter Blumencranz
    Mehran Habibi
    Steve Shivers
    Geza Acs
    Lisa E. Blumencranz
    Erin B. Yoder
    Bastiaan van der Baan
    Andrea R. Menicucci
    Patricia Dauer
    William Audeh
    Charles E. Cox
    Annals of Surgical Oncology, 2024, 31 : 393 - 394
  • [5] ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Blumencranz, Peter
    Habibi, Mehran
    Shivers, Steve
    Acs, Geza
    Blumencranz, Lisa E.
    Yoder, Erin B.
    van der Baan, Bastiaan
    Menicucci, Andrea R.
    Dauer, Patricia
    Audeh, William
    Cox, Charles E.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : 393 - 394
  • [6] Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy
    McGuire, Sean E.
    Gonzalez-Angulo, Ana M.
    Huang, Eugene H.
    Tucker, Susan L.
    Kau, Shu-Wan C.
    Yu, Tse-Kuan
    Storm, Eric A.
    Oh, Julia L.
    Woodward, Wendy A.
    Tereffe, Welela
    Hunt, Kelly K.
    Kuerer, Henry M.
    Sahin, Aysegul A.
    Hortobagyi, Gabriel N.
    Buchholz, Thomas A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (04): : 1004 - 1009
  • [7] Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
    Li, Xianjun
    Liu, Yang
    Shan, Ming
    Xu, Biagqi
    Lu, Yubo
    Zhang, Guoqiang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 1205 - 1214
  • [8] Outcomes of Hispanic/Latino women with triple negative breast cancer who achieve a complete pathologic response after neoadjuvant chemotherapy.
    Philipovskiy, Alexander
    Corral, Javier Chavez
    Heydarian, Rosalinda
    Dwivedi, Alok Kumar
    Gong Xiaoming
    Leelani, Sajid
    Gaur, Sumit
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Higher clinical lymph node stage predicts worse survival in patients with breast cancer who achieve a pathologic complete response after neoadjuvant chemotherapy
    Xie, Li-Yun
    Wang, Kun
    Shi, Yan-Xia
    Chen, Hai-Lu
    Huang, Jian-Hao
    Fan, Yang-Hang
    Qiu, Si-Qi
    Wu, Zhi-Yong
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Gonzalez-Angulo, AM
    McGuire, SE
    Buchholz, TA
    Tucker, SL
    Kuerer, HM
    Rouzier, R
    Kau, SW
    Huang, EH
    Morandi, P
    Ocana, A
    Cristofanilli, M
    Valero, V
    Buzdar, AU
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7098 - 7104